I-Mab (IMAB) Reports 83% Response Rate for Givastomig in Patients with Metastatic Gastric Cancer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 23 2025
0mins
Source: Yahoo Finance
I-Mab Overview: I-Mab (NASDAQ:IMAB) is a U.S.-based biotech company focused on precision immuno-oncology, with its lead candidate, givastomig, showing promising results in treating metastatic gastric cancer through a unique bispecific antibody approach.
Financial and Clinical Progress: The company raised approximately $61.2 million in August 2025, enhancing its financial position to support operations through late 2028, while also reporting an 83% objective response rate in Phase 1b trials for givastomig, with topline results expected in early 2026.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
